跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2010-020992-21-CZ
EUCTR2010-020992-21-CZ进行中（未招募）不适用

A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1. methotrexate or to 2. any DMARD including at least one biologic drug if patients previously failed methotrexate or to 3. methotrexate in combination with any DMARD including biologic drugs - AB1010 in treatement of patients with active rheumatoide arthritis.

AB Science0 个研究点目标入组 140 人开始时间: 2011年7月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
入组人数
140
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1.Patient with rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria for at least 6 months.
  • •2.Patient with ACR functional class I-III
  • •3.Patient who have active RA consisting of
  • •-= 6 swollen joints (over 66 swollen joints)
  • •-= 6 tender joints (over 68 tender joints)
  • •-and at least 2 out of 3 of the following:
  • •erythrocyte sedimentation rate (ESR/first hour) = 20 mm
  • •C-reactive protein (CRP) = 10 mg/L
  • •morning stiffness = 45 minutes at both screening and baseline.
  • •4.Patient who failed (defined as active RA with stable dose during 3 months) methotrexate at a dose = 15 mg/week or any DMARD including biologics drugs if patients previously failed methotrexate at a dose = 15 mg/week or methotrexate at a dose = 15 mg/week in combination with any DMARD including biologics drugs (Biologic drugs being defined as any of the following therapies: anti-TNFa, Anti-CD20, Anti-IL1, Anti-IL6, CTLA4)
  • •5.Patient with a disease onset at > 16 years of age
  • •6.Patient with an adequate organ function:
  • •Absolute neutrophils count (ANC) = 2 x 109/L
  • •White blood cells count = 4 x 109/L
  • •Haemoglobin = 10 g/dL
  • •Platelets (PTL) = 100 x 109/L
  • •AST/ALT = 3 x ULN
  • •Bilirubin = 1.5 x ULN
  • •Creatinine clearance >60 mL/min
  • •Albuminemia > 1 x LLN
  • •Proteinuria < 30 mg/dL (1+) on the dipstick; in case of proteinuria = 1+ on the dipstick, 24 hours proteinuria < 1.5g/24 hours
  • •7.Male or female patient aged 18 to 75 years, weight>50 kg, BMI between 18 and 35 kg/m²
  • •8.No active infection (tuberculosis, HIV, hepatitis, ...)
  • •9.Male or female patient of child bearing potential, must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake
  • •10.Female patient of childbearing potential must have a negative pregnant test at screening and baseline
  • •11.Patient able and willing to comply with study visits and procedures per protocol
  • •12.Patient able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol-specific procedures being performed.
  • •13.Patient able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months of treatment
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 300
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 150

排除标准

  • •1.Patient from whom the use of methotrexate is contraindicated as per its SPC (i.e. patient with severe renal or liver failure, patient with pre-existing blood dyscrasia, patient with alcohol abuse, patient with acute or chronic infection, patient with methotrexate intolerance, patient being treated with live attenuated vaccine)
  • •2.Patient with documented fibromyalgia
  • •3.Patient who have had a major surgery within 2 weeks prior to study entry
  • •4.Patient with lactose intolerance
  • •5.Patient presenting with cardiac disorders defined by at least one of the following conditions:
  • •Patient with recent cardiac history (within 6 months) of:
  • •-Acute coronary syndrome
  • •-Acute heart failure (class III or IV of the NYHA classification)
  • •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
  • •Patient with cardiac failure class III or IV of the NYHA classification
  • •Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
  • •Syncope without known aetiology within 3 months
  • •Uncontrolled severe hypertension, according to judgment of the investigator, or symptomatic hypertension
  • •6.Patient with history of primary malignancy < 5 years; except treated basal cell skin cancer or cervical carcinoma in situ
  • •7.Patient with a severe and/or uncontrolled medical condition
  • •8.Pregnant or lactating woman
  • •9.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.
  • •10.Patient who were treated with methotrexate >20 mg cannot be included in the study
  • •Previous treatments:
  • •11.Administration of a DMARD (except methotrexate) within 4 weeks (or 5 half-lives, whichever is longer) prior to baseline except for leflunomide which requires a specific wash-out period of 2 weeks before baseline and infliximab which requires a wash-out period of 8 weeks.
  • •12.Administration of more than one Non Steroidal Anti-Inflammatory Drug (NSAID) or change of dose of NSAID within 4 weeks of screening or NSAID use greater than the maximum recommended dose.
  • •13.Administration of more than 10 mg/day of prednisone or equivalent or change in the dose of prednisone or equivalent, or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids (>20 mg prednisone or equivalent) within 4 weeks of screening.
  • •14.Treatment with any investigational agent within 4 weeks of screening.

研究者

发起方
AB Science

相似试验

进行中（未招募）
不适用
Comparison of efficacy of masitinib versus methotrexate in the treatment of rheumatoid arthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid Arthritis
EUCTR2010-020992-21-DEAB Science140
进行中（未招募）
1 期
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicapSmouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicapsMedDRA version: 9.1 Level: LLT Classification code 10026891 Term: Mastocytosis
EUCTR2008-000972-25-FRAB SCIENCE200
进行中（未招募）
1 期
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap
EUCTR2008-000972-25-HUAB SCIENCE223
进行中（未招募）
1 期
Study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Indolent with handicap
EUCTR2008-000972-25-SKAb Science150
进行中（未招募）
1 期
A 24-week with possible extension study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosisSmouldering or Indolent Severe Systemic Mastocytosis with handicap unresponsive to optimal sympomatic treatmentMedDRA version: 21.1Level: PTClassification code 10042949Term: Systemic mastocytosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026891Term: MastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.1Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-001447-39-DEAB Science140